Azienda Unita Sanitaria Locale Di Piacenza — Clinical Trial Site

67 Registered trials

31 Currently recruiting

Organisation

Azienda Unita Sanitaria Locale Di Piacenza

Location

Piacenza, Italy

Identifier

ORG-100011206

Address

Via Giuseppe Taverna 49, 29121, Italy

Departments

Cardiologia e UTIC
Cardiology
DIPARTIMENTO DI ONCO-EMATOLOGIA
Dipartimento di Oncoematologia, UOC oncologia medica
DIPARTIMENTO ONCOLOGIA - EMATOLOGIA
DIPARTIMENTO ONCOLOGIA - EMATOLOGIA - UO EMATOLOGIA CENTO TRAPIANTI MIDOLLO OSSEO
Dipartimento Oncologia-Ematologia - UO EMATOLOGIA E CENTRO TRAPIANTI MIDOLLO
Divisione di Oncologia
Ematologia
General Surgery
Hematology
Medical oncology
N/A
NA
Nephrology
Nephrology and Dialysis
Oncoematologia
Oncoematology
Oncohematology
Oncologia ed Ematologia
Oncologia Medica
Oncologia Medica ed Ematologia - Ospedale Guglielmo da Saliceto -Piacenza
Oncologia-ematologia
Oncology
Oncology and Hematology
Oncology Department
Onomatology
Ospedale Guglielmo da Saliceto, Dipartimento di Oncoematologia, UOC oncologia medica
OU Nephrology and Dialysis
Pediatrics and Neonatology Units
Terapia del Dolore
U.O. Ematologia
U.O. Ematologia - Ospedale Guglielmo da Saliceto
U.O. Oncologia Medica
U.O. Oncologia Medica Via Giuseppe Taverna 49, Piacenza, 29121
U.O.Ematologia
UO Ematologia e CTMO
UO Oncologia Medica
UOC Ematologia e Centro Trapianti
UOC Nefrologia e Dialisi
UOC Nefrologia-Dialisi
UOC Pediatria e Neonatologia

Clinical trials at this site (67)

Search interface

The aim of the study is to evaluate the efficacy of Ponatinib, either alone or in combination with chemotherapy, in inducing remission in pa… Ended

2024-516868-28-00 Ph+ Acute Lymphoblastic Leukemia 4 2021-05-04
Prephase treatment with prednisone +/- Vitamin D supplementation followed by immunochemotherapy in Elderly patients with Diffuse Large B-Cel… Ended

2024-511637-35-00 Elderly patients with Diffuse Large B-Cell Lymphoma (DL 5 2021-03-23
Phase II multicenter single arm study to evaluate the efficacy and safety of ibrutinib in combination to rituximab-CHOP followed by ibrutini… Ended

2024-511641-18-00 Diffuse Large B-cell Lymphoma ABC 4 2019-08-01
Chemotherapy-free trastuzumab and pertuzumab in HER2-positive breast cancer after FDG-PET response-adapted strategy. The PHERGain study Ended

2023-509923-42-00 HER2- positive breast cancer 4 2017-07-06
Sustained treatment-free period in the course of a disease when symptoms become less severe in BCR-ABL+ chronic myeloid leukemia: a prospect… Ended

2023-510434-83-00 Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) 6 2016-10-17
A randomized phase III multicenter trial assessing efficacy and toxicity of a combination of Rituximab and Lenalidomide (R2) vs Rituximab al… Ended

2024-511640-11-00 Follicular lymphoma 5 2014-05-15
Use of circulating tumor dna test to intensify post-operative treatment of patients with resected colon cancer. Halted

2024-515152-20-00 Stage III and high-risk stage II resected colon cancer 4 2023-03-02
Phase 2/3 Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer Ended

2022-502196-31-00 Advanced or Recurrent Endometrial Cancer 10 2023-08-21
VISIONARY Trial: Phase 3 Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN) Ended

2022-500079-30-00 IgA Nephropathy 5 2022-11-03
Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed S… Ended

2024-513559-34-00 Small Cell Lung Cancer (SCLC) 5 2022-07-19
A phase 2, multicenter, randomized, double blind, active controlled, parallel group study assessing the analgesic effect and safety of two d… Ended

2024-513940-27-00 Chronic low back pain 4 2021-11-19
A randomized, 2-arm, open-label, phase II study of abemaciclib combined with endocrine therapy (letrozole or fulvestrant) with or without a … Ended

2023-509591-42-00 HR-positive/HER2-negative breast cancer 4 2021-05-04
Rituximab, bendamustine and cytarabine followed by venetoclax (V-RBAC) in high-risk elderly patients with mantle cell lymphoma (MCL) Ended

2024-511533-35-00 Mantle Cell Lymphoma 4 2018-09-03
autologous Transplantation after a Rituximab/Ibrutinib/Ara-c containing iNduction in Generalized mantle cell Lymphoma – a randomized Europea… Ended

2024-511235-10-00 Generalized mantle cell Lymphoma 5 2016-07-25
Adjuvant Treatment for High-risk Triple Negative Breast Cancer Patients With the Anti-PD-l1 Antibody Avelumab (A-Brave) Ended

2024-514515-10-00 Breast Cancer 5 2016-06-16
ROMIDEPSIN IN COMBINATION WITH CHOEP AS FIRST LINE TREATMENT BEFORE HEMATOPOIETIC STEM CELL TRANSPLANTATION IN YOUNG PATIENTS WITH NODAL PER… Ended

2024-511639-83-00 Anaplastic Large T-cell Lymphoma ALK negative 9 2014-09-01
Clinical trial addressing the efficacy of first-line Chlamydophila psittaci-eradicating therapy with protracted administration of doxycyclin… Ended

2024-513426-29-00 Patients with newly diagnosed Ocular Adnexal Marginal Z 4 2013-03-19
Randomized, single blind, non-inferiority study on the speed of action of lysin ibuprofen suspension vs ibuprofen suspension in the treatmen… Ended

2023-507510-27-00 Acute pain in pediatric age 6
Electrochemotherapy as a first line treatment in recurrent squamous cell carcinoma of the oral cavity and oropharynx: a randomized controlle… Ended

2025-520735-16-00 CARCINOMA OF THE ORAL CAVITY AND OROPHARYNX 4